Jiandong Wang
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Jiandong Wang has a total of 54 co-authors. Here are the top co-authors by number of shared publications:
- Songkun Gao
Gynecologic Oncology Department, Beijing Obstetrics and Gynecology Hospital, Capital Medical University, Beijing Maternal and Child Health Care Hospital, Beijing, People’s Republic of China
6 shared publications - Tong Wang
Gynecologic Oncology Department,Beijing Obstetrics and Gynecology Hospital, Capital Medical University, Beijing Maternal and Child Health Care Hospital, Beijing, 100026, People’s Republic of China
4 shared publications - Boer Deng
Department of Gynecologic Oncology, Beijing Obstetrics and Gynecology Hospital, Capital Medical University, Beijing Maternal and Child Health Care Hospital, Beijing 100026, China
2 shared publications - Chunxiao Zhou
Division of Gynecologic Oncology, University of North Carolina at Chapel Hill, Chapel Hill, NC 27599, USA
2 shared publications Di Bo
Department of Obstetrics, Beijing Obstetrics and Gynecology Hospital, Capital Medical University, Beijing, People's Republic of China
2 shared publicationsFang Song
Department of Gynecologic Oncology, Beijing Obstetrics and Gynecology Hospital, Capital Medical University, Beijing Maternal and Child Health Care Hospital, Beijing, 100026, People’s Republic of China
2 shared publications
Latest Publications
- Open Access
Mechanism-Driven Evolution of Fertility-Sparing Treatment and Precision Management of Special Populations in Endometrial Cancer: A Review
Endometrial cancer is increasingly diagnosed in patients who have not yet completed childbearing. For carefully selected patients with grade 1 endometrioid endometrial carcinoma confined to the endometrium, fertility-sparing treatment (FST) can preserve reproductive potential but requires rigorous histologic surveillance. In eligible patients, oral progestins and/or the levonorgestrel-releasing intrauterine system (LNG-IUS) remain the mainstay of fertility-sparing treatment, with hysteroscopic lesion resection incorporated in selected cases. Obesity, polycystic ovary syndrome, abnormalities in glucose metabolism, molecular subtype, and primary or acquired progestin resistance collectively contribute to heterogeneity in treatment response and the risk of recurrence. This narrative review critically integrates current guidelines, randomized controlled trials, prospective studies, retrospective cohorts, and early exploratory evidence to evaluate the biological rationale, clinical positioning, efficacy, safety, and maturity of evidence for progestin-based therapy, metabolic interventions, combined endocrine approaches, molecularly guided strategies, and exploratory immunotherapeutic approaches. We further propose an integrated clinical pathway encompassing candidate selection, molecular assessment, response evaluation, transition to pregnancy, retreatment after recurrence, and timely conversion to definitive surgery. Importantly, this review distinguishes guideline-supported approaches from adjunctive, investigational, and exploratory strategies. Major evidence gaps include inconsistent definitions of treatment response, limited prospective molecularly stratified data, uncertain reproductive safety of emerging systemic therapies, and insufficient long-term data on pregnancy outcomes and offspring.
Open AccessMechanism-Driven Evolution of Fertility-Sparing Treatment and Precision Management of Special Populations in Endometrial Cancer: A Review
Endometrial cancer is increasingly diagnosed in patients who have not yet completed childbearing. For carefully selected patients with grade 1 endometrioid endometrial carcinoma confined to the endometrium, fertility-sparing treatment (FST) can preserve reproductive potential but requires rigorous histologic surveillance. In eligible patients, oral progestins and/or the levonorgestrel-releasing intrauterine system (LNG-IUS) remain the mainstay of fertility-sparing treatment, with hysteroscopic lesion resection incorporated in selected cases. Obesity, polycystic ovary syndrome, abnormalities in glucose metabolism, molecular subtype, and primary or acquired progestin resistance collectively contribute to heterogeneity in treatment response and the risk of recurrence. This narrative review critically integrates current guidelines, randomized controlled trials, prospective studies, retrospective cohorts, and early exploratory evidence to evaluate the biological rationale, clinical positioning, efficacy, safety, and maturity of evidence for progestin-based therapy, metabolic interventions, combined endocrine approaches, molecularly guided strategies, and exploratory immunotherapeutic approaches. We further propose an integrated clinical pathway encompassing candidate selection, molecular assessment, response evaluation, transition to pregnancy, retreatment after recurrence, and timely conversion to definitive surgery. Importantly, this review distinguishes guideline-supported approaches from adjunctive, investigational, and exploratory strategies. Major evidence gaps include inconsistent definitions of treatment response, limited prospective molecularly stratified data, uncertain reproductive safety of emerging systemic therapies, and insufficient long-term data on pregnancy outcomes and offspring.
- Open Access
- 1 July 2025
- Published by Taylor & Francis in International Journal of Women's Health
- Vol. ume 17, 2109-2119
Comparison of the Efficacy of Polyvinyl Alcohol Colorless Embolic Microspheres (8Spheres) and Gelatin Embolic Microspheres (Embosphere) in Uterine Artery Embolization for Symptomatic Uterine Fibroids in Women Without Fertility Requirements: A Multicenter Observational Study
Objective: To evaluate the differences in efficacy between polyvinyl alcohol colorless embolic microspheres (8Spheres®) and gelatin embolic microspheres (Embosphere®) in uterine artery embolization for symptomatic uterine fibroids. Methods: We included 259 patients from 12 hospitals who underwent uterine artery embolization for symptomatic uterine fibroids. We collected preoperative general conditions, menstrual status, and uterine and fibroid sizes as indicated by magnetic resonance imaging, as well as changes in ovarian hormone levels before and 6 months after the procedure. Differences in uterine fibroid scores and health-related quality of life scores between the two types of microspheres were compared using analysis of covariance (ANCOVA). Differences in the largest fibroid volume, uterine volume, total menstrual bleeding score, and ovarian hormone levels were compared using T-tests or Mann–Whitney U-tests. Results: There was no significant difference in clinical efficacy between the two types of microspheres at 6 months postoperatively (P=0.4081). No significant differences were observed in uterine fibroid volume or symptom-related scores.There were no significant differences in ovarian hormone levels between the two groups or within each group before and after the procedure. Conclusion: The use of 8Spheres® is effective for symptomatic uterine fibroids and is comparable to the currently clinically used Embosphere® microspheres in terms of efficacy for symptomatic uterine fibroids.
- 1 July 2025
- Published by Taylor & Francis in International Journal of Women's Health
- Vol. ume 17, 2109-2119
Open AccessComparison of the Efficacy of Polyvinyl Alcohol Colorless Embolic Microspheres (8Spheres) and Gelatin Embolic Microspheres (Embosphere) in Uterine Artery Embolization for Symptomatic Uterine Fibroids in Women Without Fertility Requirements: A Multicenter Observational Study
Objective: To evaluate the differences in efficacy between polyvinyl alcohol colorless embolic microspheres (8Spheres®) and gelatin embolic microspheres (Embosphere®) in uterine artery embolization for symptomatic uterine fibroids. Methods: We included 259 patients from 12 hospitals who underwent uterine artery embolization for symptomatic uterine fibroids. We collected preoperative general conditions, menstrual status, and uterine and fibroid sizes as indicated by magnetic resonance imaging, as well as changes in ovarian hormone levels before and 6 months after the procedure. Differences in uterine fibroid scores and health-related quality of life scores between the two types of microspheres were compared using analysis of covariance (ANCOVA). Differences in the largest fibroid volume, uterine volume, total menstrual bleeding score, and ovarian hormone levels were compared using T-tests or Mann–Whitney U-tests. Results: There was no significant difference in clinical efficacy between the two types of microspheres at 6 months postoperatively (P=0.4081). No significant differences were observed in uterine fibroid volume or symptom-related scores.There were no significant differences in ovarian hormone levels between the two groups or within each group before and after the procedure. Conclusion: The use of 8Spheres® is effective for symptomatic uterine fibroids and is comparable to the currently clinically used Embosphere® microspheres in terms of efficacy for symptomatic uterine fibroids.
- Open Access
- 1 May 2025
- Published by Taylor & Francis in Risk Management and Healthcare Policy
- Vol. ume 18, 1783-1791
Assessment of the Real-Time Photoelectric Detection Device (TruScreen) in Screening for Cervical Precancerous Lesions in Middle-Aged Women: An Observational Study
Objective: To evaluate the efficacy of a real-time photoelectric element (TruScreen) for identifying cervical precancerous lesions in middle-aged women. Methods: We conducted a retrospective analysis of data collected from 100 women aged 25– 55 years who underwent colposcopy at Beijing Obstetrics and Gynecology Hospital between June and July 2018. We obtained the results of the ThinPrep cytologic test/HPV tests and TruScreen tests conducted before colposcopy as well as the histopathological results from postoperative multi-site biopsies. Patients were divided into two groups based on histopathological findings: CIN II or higher, and CIN I. We analyzed the diagnostic efficacy of different testing methods, alone and in combination, for cervical precancerous lesions. Results: TruScreen demonstrated good specificity (74.4%) and sensitivity (86.4%) for detecting CIN II or higher lesions, superior to those of TCT alone (sensitivity, 81.8%; specificity, 38.2%) and HPV testing alone (sensitivity, 81.8%; specificity, 28.2%). When different testing methods were combined, the sensitivity of TCT+HR-HPV, TruScreen+HR-HPV, and TruScreen+HR-HPV+TCT reached 100%, while the highest specificity was observed with TruScreen+HR-HPV (25.6%). Conclusion: TruScreen showed high accuracy and specificity for screening cervical precancerous lesions in middle-aged women. The sensitivity and specificity can be improved when combined with HR-HPV test and TCT test. TruScreen has low sampling requirements for clinicians and does not require laboratory doctors or pathologists equipped with PCR equipment to verify. Given its minimal dependence on medical conditions, TruScreen can be considered a potential supplementary screening tool for cervical precancerous lesions.
- 1 May 2025
- Published by Taylor & Francis in Risk Management and Healthcare Policy
- Vol. ume 18, 1783-1791
Open AccessAssessment of the Real-Time Photoelectric Detection Device (TruScreen) in Screening for Cervical Precancerous Lesions in Middle-Aged Women: An Observational Study
Objective: To evaluate the efficacy of a real-time photoelectric element (TruScreen) for identifying cervical precancerous lesions in middle-aged women. Methods: We conducted a retrospective analysis of data collected from 100 women aged 25– 55 years who underwent colposcopy at Beijing Obstetrics and Gynecology Hospital between June and July 2018. We obtained the results of the ThinPrep cytologic test/HPV tests and TruScreen tests conducted before colposcopy as well as the histopathological results from postoperative multi-site biopsies. Patients were divided into two groups based on histopathological findings: CIN II or higher, and CIN I. We analyzed the diagnostic efficacy of different testing methods, alone and in combination, for cervical precancerous lesions. Results: TruScreen demonstrated good specificity (74.4%) and sensitivity (86.4%) for detecting CIN II or higher lesions, superior to those of TCT alone (sensitivity, 81.8%; specificity, 38.2%) and HPV testing alone (sensitivity, 81.8%; specificity, 28.2%). When different testing methods were combined, the sensitivity of TCT+HR-HPV, TruScreen+HR-HPV, and TruScreen+HR-HPV+TCT reached 100%, while the highest specificity was observed with TruScreen+HR-HPV (25.6%). Conclusion: TruScreen showed high accuracy and specificity for screening cervical precancerous lesions in middle-aged women. The sensitivity and specificity can be improved when combined with HR-HPV test and TCT test. TruScreen has low sampling requirements for clinicians and does not require laboratory doctors or pathologists equipped with PCR equipment to verify. Given its minimal dependence on medical conditions, TruScreen can be considered a potential supplementary screening tool for cervical precancerous lesions.
- Top Cited PapersOpen Access
- 1 March 2025
- Published by Taylor & Francis in International Journal of Women's Health
- Vol. ume 17, 651-662
Global Trends in Incidence and Mortality Rates of Endometrial Cancer Among Individuals Aged 55 years and Above From 1990 to 2021: An Analysis of the Global Burden of Disease
Purpose: To describe the temporal trend of endometrial burden in postmenopausal women aged 55 years and above worldwide from 1990 to 2021, evaluate the age cohort effect, explore its influencing factors, and predict the disease burden in the next 15 years. Patients and Methods: Using Joinpoint regression, data from the 2021 Global Burden of Disease Study were assessed for changes in endometrial cancer incidence rate, morbidity, and mortality in postmenopausal women aged 55 years and above. Age period cohort analysis helped estimate age, period, and cohort effects. The Das Gupta method helped analyze effects of different factors on endometrial cancer incidence and mortality among postmenopausal patients. ARIMA helped predict the endometrial cancer disease burden in postmenopausal women from 2022 to 2036. Results: In 2021, globally, there were 360253 (326,176– 388545) cases and 84630 (75,523– 93215) deaths among postmenopausal patients with endometrial cancer. During 1990– 2021, the global endometrial cancer incidence in postmenopausal women gradually increased, while the mortality rate gradually decreased. Changes in disease incidence and mortality rates are mainly due to population growth and epidemiological changes, with little influence of age. The risk of endometrial cancer in postmenopausal women gradually increased with age, using age, period, and cohort average as the reference groups. The mortality rate decreased gradually decreased in 2019 and continued to rise thereafter. It is expected that by 2036, the incidence of endometrial cancer in postmenopausal women aged 55 years and above will increase by 6.5%, and the mortality rate will decrease by 8.0%. Conclusion: The number of patients with postmenopausal endometrial cancer aged 55 years and above is still increasing, and it is necessary to establish a comprehensive screening and treatment mechanism to ensure prolongation of patient lifespan.
- 1 March 2025
- Published by Taylor & Francis in International Journal of Women's Health
- Vol. ume 17, 651-662
Top Cited PapersOpen AccessGlobal Trends in Incidence and Mortality Rates of Endometrial Cancer Among Individuals Aged 55 years and Above From 1990 to 2021: An Analysis of the Global Burden of Disease
Purpose: To describe the temporal trend of endometrial burden in postmenopausal women aged 55 years and above worldwide from 1990 to 2021, evaluate the age cohort effect, explore its influencing factors, and predict the disease burden in the next 15 years. Patients and Methods: Using Joinpoint regression, data from the 2021 Global Burden of Disease Study were assessed for changes in endometrial cancer incidence rate, morbidity, and mortality in postmenopausal women aged 55 years and above. Age period cohort analysis helped estimate age, period, and cohort effects. The Das Gupta method helped analyze effects of different factors on endometrial cancer incidence and mortality among postmenopausal patients. ARIMA helped predict the endometrial cancer disease burden in postmenopausal women from 2022 to 2036. Results: In 2021, globally, there were 360253 (326,176– 388545) cases and 84630 (75,523– 93215) deaths among postmenopausal patients with endometrial cancer. During 1990– 2021, the global endometrial cancer incidence in postmenopausal women gradually increased, while the mortality rate gradually decreased. Changes in disease incidence and mortality rates are mainly due to population growth and epidemiological changes, with little influence of age. The risk of endometrial cancer in postmenopausal women gradually increased with age, using age, period, and cohort average as the reference groups. The mortality rate decreased gradually decreased in 2019 and continued to rise thereafter. It is expected that by 2036, the incidence of endometrial cancer in postmenopausal women aged 55 years and above will increase by 6.5%, and the mortality rate will decrease by 8.0%. Conclusion: The number of patients with postmenopausal endometrial cancer aged 55 years and above is still increasing, and it is necessary to establish a comprehensive screening and treatment mechanism to ensure prolongation of patient lifespan.
- Open Access
- 19 February 2025
- Published by Springer Nature in BMC Women's Health
- Vol. 25 (1) , 1-7
Cervical cancer screening: comparative study of human papillomavirus detection between cervical cytology and urine samples
To evaluate the efficacy of urine-based human papillomavirus detection in detecting high-grade cervical lesions (CIN2+) compared to cervical cytology examination. The data of 458 patients with cytological abnormalities and/or positive human papillomavirus test results were retrospectively selected from December 1, 2017, to March 31, 2022, at the Beijing Obstetrics and Gynecology Hospital affiliated with Capital Medical University. Cervical cytology and urine samples were used to detect human papillomavirus status and analyze the correlation between the results and cervical biopsy results. Among the selected 458 samples, 386 were positive for human papillomavirus through cervical cytology examination, with a detection rate of 84.3%. Out of 458 urine samples, 362 were positive, with a detection rate of 79.0%. The data shows a high consistency between cervical cytology and urine sample testing, with a kappa value of 0.637 (P < 0.01). The most prevalent subtypes in cervical samples included HPV16, HPV58, and HPV52, while the detection rates of HPV16 and HPV58 subtypes were relatively high in urine samples. The comparison of subtype distribution between cervical and urine samples showed that the positivity rate of HPV44 subtype was consistent, both at 3.9%. Among the five HPV subtypes corresponding to the HPV nine-valent vaccine, the kappa value of HPV16 in cervical and urine samples was 0.791 (P < 0.05), the kappa value of HPV52 was 0.766 (P < 0.05), HPV18 was 0.762 (P < 0.05), HPV33 was 0.539 (P < 0.01), and HPV31 was 0.458 (P < 0.05). Among 458 specimens, the sensitivity of human papillomavirus detection in cervical cytology was 96.7%, with a specificity of 20.2% (P < 0.01). The sensitivity of human papillomavirus detection in urine samples was 85.2%, with a specificity of 23.2% (P < 0.01). Urine human papillomavirus testing, as a non-invasive screening method, has significant application effects. The screening results are highly consistent with cervical cytology screening and may improve the compliance of women who do not want to undergo invasive gynecological examinations. This screening method simplifies the screening process and has great potential in screening cancer lesions and preventing cervical cancer.
- 19 February 2025
- Published by Springer Nature in BMC Women's Health
- Vol. 25 (1) , 1-7
Open AccessCervical cancer screening: comparative study of human papillomavirus detection between cervical cytology and urine samples
To evaluate the efficacy of urine-based human papillomavirus detection in detecting high-grade cervical lesions (CIN2+) compared to cervical cytology examination. The data of 458 patients with cytological abnormalities and/or positive human papillomavirus test results were retrospectively selected from December 1, 2017, to March 31, 2022, at the Beijing Obstetrics and Gynecology Hospital affiliated with Capital Medical University. Cervical cytology and urine samples were used to detect human papillomavirus status and analyze the correlation between the results and cervical biopsy results. Among the selected 458 samples, 386 were positive for human papillomavirus through cervical cytology examination, with a detection rate of 84.3%. Out of 458 urine samples, 362 were positive, with a detection rate of 79.0%. The data shows a high consistency between cervical cytology and urine sample testing, with a kappa value of 0.637 (P < 0.01). The most prevalent subtypes in cervical samples included HPV16, HPV58, and HPV52, while the detection rates of HPV16 and HPV58 subtypes were relatively high in urine samples. The comparison of subtype distribution between cervical and urine samples showed that the positivity rate of HPV44 subtype was consistent, both at 3.9%. Among the five HPV subtypes corresponding to the HPV nine-valent vaccine, the kappa value of HPV16 in cervical and urine samples was 0.791 (P < 0.05), the kappa value of HPV52 was 0.766 (P < 0.05), HPV18 was 0.762 (P < 0.05), HPV33 was 0.539 (P < 0.01), and HPV31 was 0.458 (P < 0.05). Among 458 specimens, the sensitivity of human papillomavirus detection in cervical cytology was 96.7%, with a specificity of 20.2% (P < 0.01). The sensitivity of human papillomavirus detection in urine samples was 85.2%, with a specificity of 23.2% (P < 0.01). Urine human papillomavirus testing, as a non-invasive screening method, has significant application effects. The screening results are highly consistent with cervical cytology screening and may improve the compliance of women who do not want to undergo invasive gynecological examinations. This screening method simplifies the screening process and has great potential in screening cancer lesions and preventing cervical cancer.
- Open Access
- 1 January 2025
- Published by Taylor & Francis in International Journal of Women's Health
- Vol. ume 17, 201-209
Do Human Papilloma Virus and Cytological Testing Results Before Colposcopy Alter the Pathological Grading of Colposcopy Acetic Acid Visual Examination?: A Retrospective Study
Objective: To understand whether human papillomavirus (HPV) and cytological testing (TCT [ie, “thinprep” cytological testing]) results can provide more information beyond visual information for vaginal colposcopy examinations to upgrade or downgrade the visual diagnosis of vaginal colposcopy. Patients and Methods: Data from 519 patients, who underwent vaginal colposcopy at the Beijing Obstetrics and Gynecology Hospital (Beijing, China) between January and June 2020, were included. Preoperative HPV and TCT results were statistically analyzed, and were divided into 3 groups according to postoperative cervical tissue pathological diagnosis: negative; low-grade squamous intraepithelial (LSIL); and high-grade squamous intraepithelial lesion (HSIL). Positive and negative predictive values for cervical inflammation, LSIL, and HSIL in patients diagnosed using vaginal colposcopy, based on cervical pathological grouping, and differences in HPV and TCT results among patients who underwent vaginal colposcopy, were analyzed. Results: The age of patients diagnosed with cervicitis, LSIL, and HSIL using colposcopy gradually decreased, and the proportion of HPV16/18 infection in the HSIL group was significantly higher than the other 2 groups. There were significant differences in TCT results among the groups. According to pathological results from cervical tissue specimens, among all groups diagnosed using colposcopy, the age of the HSIL group was significantly younger than that of the other groups, and the proportion of patients with a TCT greater than LSIL was significantly higher than that of the other groups. Conclusion: HPV did not provide additional information for vaginal colposcopy. Young(er) patients and those with a TCT greater than LSIL may consider upgrading the vaginal colposcopy diagnosis based on imaging information.
- 1 January 2025
- Published by Taylor & Francis in International Journal of Women's Health
- Vol. ume 17, 201-209
Open AccessDo Human Papilloma Virus and Cytological Testing Results Before Colposcopy Alter the Pathological Grading of Colposcopy Acetic Acid Visual Examination?: A Retrospective Study
Objective: To understand whether human papillomavirus (HPV) and cytological testing (TCT [ie, “thinprep” cytological testing]) results can provide more information beyond visual information for vaginal colposcopy examinations to upgrade or downgrade the visual diagnosis of vaginal colposcopy. Patients and Methods: Data from 519 patients, who underwent vaginal colposcopy at the Beijing Obstetrics and Gynecology Hospital (Beijing, China) between January and June 2020, were included. Preoperative HPV and TCT results were statistically analyzed, and were divided into 3 groups according to postoperative cervical tissue pathological diagnosis: negative; low-grade squamous intraepithelial (LSIL); and high-grade squamous intraepithelial lesion (HSIL). Positive and negative predictive values for cervical inflammation, LSIL, and HSIL in patients diagnosed using vaginal colposcopy, based on cervical pathological grouping, and differences in HPV and TCT results among patients who underwent vaginal colposcopy, were analyzed. Results: The age of patients diagnosed with cervicitis, LSIL, and HSIL using colposcopy gradually decreased, and the proportion of HPV16/18 infection in the HSIL group was significantly higher than the other 2 groups. There were significant differences in TCT results among the groups. According to pathological results from cervical tissue specimens, among all groups diagnosed using colposcopy, the age of the HSIL group was significantly younger than that of the other groups, and the proportion of patients with a TCT greater than LSIL was significantly higher than that of the other groups. Conclusion: HPV did not provide additional information for vaginal colposcopy. Young(er) patients and those with a TCT greater than LSIL may consider upgrading the vaginal colposcopy diagnosis based on imaging information.
- Open Access
- 1 December 2024
- Published by Taylor & Francis in International Journal of Women's Health
- Vol. ume 16, 2355-2363
Is Insulin Resistance a High-Risk Factor for Postmenopausal Endometrial Cancer: Insights from the Triglyceride Glucose (TyG) Index and the Metabolic Score for Insulin Resistance (METS-IR)
Purpose: To evaluate the insulin resistance in patients with menopause who were newly diagnosed with endometrial cancer and its association with disease development. Methods: The study included 356 patients with menopause who underwent hysteroscopy at Beijing Obstetrics and Gynecology Hospital between September 2013 and July 2018. Data on age, height, weight, menarche and menopausal age, pregnancies, births, and family history of tumors, hypertension, and diabetes were collected. Blood tests provided fasting blood glucose, triglycerides, total cholesterol, high-density lipoprotein, and low-density lipoprotein levels. Pathological testing determined whether patients had endometrial cancer or precancerous lesions. Differences in influencing factors between patients with endometrial cancer or precancerous lesions and those with normal or benign conditions were analyzed using univariate analysis. Quartile grouping of the Metabolic Score for Insulin Resistance (METS-IR) and Triglyceride-Glucose (TyG) index were applied to examine the impact of different insulin resistance on the development of endometrial cancer or precancerous lesions. Results: Univariate analysis revealed that the proportion of patients with hypertension and diabetes was significantly higher among those with endometrial cancer and precancerous lesions. METS-IR and TyG levels were significantly increased in patients with endometrial cancer and precancerous lesions. The quartile grouping results of METS-IR and TyG suggested that age, BMI, FBG, TG, hypertension, and diabetes prevalence rates increased with an increase in METS-IR or TyG, whereas lipid indicators were negatively correlated and unstable Logistic regression suggested that none of the above influencing factors and METS-IR or TyG were related to the pathological results of the patients. Conclusion: Patients with endometrial or precancerous lesions showed evidence of insulin resistance compared to others, though this was not directly associated with disease presence. This study provides relevant information for preventing of endometrial cancer in the future. Larger studies are needed to evaluate the role of METS-IR and TyG in endometrial cancer prevention.
- 1 December 2024
- Published by Taylor & Francis in International Journal of Women's Health
- Vol. ume 16, 2355-2363
Open AccessIs Insulin Resistance a High-Risk Factor for Postmenopausal Endometrial Cancer: Insights from the Triglyceride Glucose (TyG) Index and the Metabolic Score for Insulin Resistance (METS-IR)
Purpose: To evaluate the insulin resistance in patients with menopause who were newly diagnosed with endometrial cancer and its association with disease development. Methods: The study included 356 patients with menopause who underwent hysteroscopy at Beijing Obstetrics and Gynecology Hospital between September 2013 and July 2018. Data on age, height, weight, menarche and menopausal age, pregnancies, births, and family history of tumors, hypertension, and diabetes were collected. Blood tests provided fasting blood glucose, triglycerides, total cholesterol, high-density lipoprotein, and low-density lipoprotein levels. Pathological testing determined whether patients had endometrial cancer or precancerous lesions. Differences in influencing factors between patients with endometrial cancer or precancerous lesions and those with normal or benign conditions were analyzed using univariate analysis. Quartile grouping of the Metabolic Score for Insulin Resistance (METS-IR) and Triglyceride-Glucose (TyG) index were applied to examine the impact of different insulin resistance on the development of endometrial cancer or precancerous lesions. Results: Univariate analysis revealed that the proportion of patients with hypertension and diabetes was significantly higher among those with endometrial cancer and precancerous lesions. METS-IR and TyG levels were significantly increased in patients with endometrial cancer and precancerous lesions. The quartile grouping results of METS-IR and TyG suggested that age, BMI, FBG, TG, hypertension, and diabetes prevalence rates increased with an increase in METS-IR or TyG, whereas lipid indicators were negatively correlated and unstable Logistic regression suggested that none of the above influencing factors and METS-IR or TyG were related to the pathological results of the patients. Conclusion: Patients with endometrial or precancerous lesions showed evidence of insulin resistance compared to others, though this was not directly associated with disease presence. This study provides relevant information for preventing of endometrial cancer in the future. Larger studies are needed to evaluate the role of METS-IR and TyG in endometrial cancer prevention.
- Open Access
- 20 May 2024
- Published by MDPI AG in Biomolecules
- Vol. 14 (5) , 601
Palmitic Acid Exerts Anti-Tumorigenic Activities by Modulating Cellular Stress and Lipid Droplet Formation in Endometrial Cancer
Epidemiological and clinical evidence have extensively documented the role of obesity in the development of endometrial cancer. However, the effect of fatty acids on cell growth in endometrial cancer has not been widely studied. Here, we reported that palmitic acid significantly inhibited cell proliferation of endometrial cancer cells and primary cultures of endometrial cancer and reduced tumor growth in a transgenic mouse model of endometrial cancer, in parallel with increased cellular stress and apoptosis and decreased cellular adhesion and invasion. Inhibition of cellular stress by N-acetyl-L-cysteine effectively reversed the effects of palmitic acid on cell proliferation, apoptosis, and invasive capacity in endometrial cancer cells. Palmitic acid increased the intracellular formation of lipid droplets in a time- and dose-dependent manner. Depletion of lipid droplets by blocking DGAT1 and DGAT2 effectively increased the ability of palmitic acid to inhibit cell proliferation and induce cleaved caspase 3 activity. Collectively, this study provides new insight into the effect of palmitic acid on cell proliferation and invasion and the formation of lipid droplets that may have potential clinical relevance in the treatment of obesity-driven endometrial cancer.
- 20 May 2024
- Published by MDPI AG in Biomolecules
- Vol. 14 (5) , 601
Open AccessPalmitic Acid Exerts Anti-Tumorigenic Activities by Modulating Cellular Stress and Lipid Droplet Formation in Endometrial Cancer
Epidemiological and clinical evidence have extensively documented the role of obesity in the development of endometrial cancer. However, the effect of fatty acids on cell growth in endometrial cancer has not been widely studied. Here, we reported that palmitic acid significantly inhibited cell proliferation of endometrial cancer cells and primary cultures of endometrial cancer and reduced tumor growth in a transgenic mouse model of endometrial cancer, in parallel with increased cellular stress and apoptosis and decreased cellular adhesion and invasion. Inhibition of cellular stress by N-acetyl-L-cysteine effectively reversed the effects of palmitic acid on cell proliferation, apoptosis, and invasive capacity in endometrial cancer cells. Palmitic acid increased the intracellular formation of lipid droplets in a time- and dose-dependent manner. Depletion of lipid droplets by blocking DGAT1 and DGAT2 effectively increased the ability of palmitic acid to inhibit cell proliferation and induce cleaved caspase 3 activity. Collectively, this study provides new insight into the effect of palmitic acid on cell proliferation and invasion and the formation of lipid droplets that may have potential clinical relevance in the treatment of obesity-driven endometrial cancer.
- Open Access
- 19 May 2024
- Published by MDPI AG in Antioxidants
- Vol. 13 (5) , 617
Review of the Potential Role of Ascorbate in the Prevention and Treatment of Gynecological Cancers
Ascorbate (vitamin C) is an essential vitamin for the human body and participates in various physiological processes as an important coenzyme and antioxidant. Furthermore, the role of ascorbate in the prevention and treatment of cancer including gynecological cancer has gained much more interest recently. The bioavailability and certain biological functions of ascorbate are distinct in males versus females due to differences in lean body mass, sex hormones, and lifestyle factors. Despite epidemiological evidence that ascorbate-rich foods and ascorbate plasma concentrations are inversely related to cancer risk, ascorbate has not demonstrated a significant protective effect in patients with gynecological cancers. Adequate ascorbate intake may have the potential to reduce the risk of human papillomavirus (HPV) infection and high-risk HPV persistence status. High-dose ascorbate exerts antitumor activity and synergizes with chemotherapeutic agents in preclinical cancer models of gynecological cancer. In this review, we provide evidence for the biological activity of ascorbate in females and discuss the potential role of ascorbate in the prevention and treatment of ovarian, endometrial, and cervical cancers.
- 19 May 2024
- Published by MDPI AG in Antioxidants
- Vol. 13 (5) , 617
Open AccessReview of the Potential Role of Ascorbate in the Prevention and Treatment of Gynecological Cancers
Ascorbate (vitamin C) is an essential vitamin for the human body and participates in various physiological processes as an important coenzyme and antioxidant. Furthermore, the role of ascorbate in the prevention and treatment of cancer including gynecological cancer has gained much more interest recently. The bioavailability and certain biological functions of ascorbate are distinct in males versus females due to differences in lean body mass, sex hormones, and lifestyle factors. Despite epidemiological evidence that ascorbate-rich foods and ascorbate plasma concentrations are inversely related to cancer risk, ascorbate has not demonstrated a significant protective effect in patients with gynecological cancers. Adequate ascorbate intake may have the potential to reduce the risk of human papillomavirus (HPV) infection and high-risk HPV persistence status. High-dose ascorbate exerts antitumor activity and synergizes with chemotherapeutic agents in preclinical cancer models of gynecological cancer. In this review, we provide evidence for the biological activity of ascorbate in females and discuss the potential role of ascorbate in the prevention and treatment of ovarian, endometrial, and cervical cancers.
- Open Access
- 1 November 2023
- Published by Taylor & Francis in International Journal of Women's Health
- Vol. ume 15, 1681-1691
The Effect of Cervical Cold-Knife Conization (CKC) on HPV Infection in Patients with High-Grade Cervical Intraepithelial Neoplasia: A Retrospective Study
Purpose: Investigation of HPV infection treatment in women undergoing cervical cold-knife conization for advanced cervical intraepithelial neoplasia. Patients and Methods: A retrospective analysis was conducted on patients who underwent cervical cold-knife conization for cervical intraepithelial neoplasia grade II–III at Beijing Obstetrics and Gynecology Hospital from January 2017 to December 2018. The HPV infection status of the patients at 6 months, 1 year, and 2 years after surgery was collected. We use chi square analysis and binary logistic regression to evaluate various factors such as age, number of pregnancies, number of cesarean sections, number of vaginal deliveries, HPV type, size of surgical specimens (diameter and height), and the influence of specimen edge on HPV infection. Results: A total of 334 patients were included in the analysis. The patients are mainly infected with HPV 16/58/52. Age is a influencing factor for HPV recovery 12 months after CKC surgery (P=0.002). Based on the diagnosis of HPV one year after CKC, the recovery rate of HPV58 patients is significantly lower than HPV16. Age is a influencing factor for the recovery of HPV infection (P< 0.05). Conclusion: The treatment of HPV infection by CKC is related to the patient’s age and HPV subtype but not to number of pregnancies, number of pregnancies, number of vaginal deliveries, size of surgical specimens, and marginal conditions. The rate of HPV negative conversion is relatively high 24 months after the patient does not undergo surgery, but there is currently a lack of data on cervical lesions that match HPV results.
- 1 November 2023
- Published by Taylor & Francis in International Journal of Women's Health
- Vol. ume 15, 1681-1691
Open AccessThe Effect of Cervical Cold-Knife Conization (CKC) on HPV Infection in Patients with High-Grade Cervical Intraepithelial Neoplasia: A Retrospective Study
Purpose: Investigation of HPV infection treatment in women undergoing cervical cold-knife conization for advanced cervical intraepithelial neoplasia. Patients and Methods: A retrospective analysis was conducted on patients who underwent cervical cold-knife conization for cervical intraepithelial neoplasia grade II–III at Beijing Obstetrics and Gynecology Hospital from January 2017 to December 2018. The HPV infection status of the patients at 6 months, 1 year, and 2 years after surgery was collected. We use chi square analysis and binary logistic regression to evaluate various factors such as age, number of pregnancies, number of cesarean sections, number of vaginal deliveries, HPV type, size of surgical specimens (diameter and height), and the influence of specimen edge on HPV infection. Results: A total of 334 patients were included in the analysis. The patients are mainly infected with HPV 16/58/52. Age is a influencing factor for HPV recovery 12 months after CKC surgery (P=0.002). Based on the diagnosis of HPV one year after CKC, the recovery rate of HPV58 patients is significantly lower than HPV16. Age is a influencing factor for the recovery of HPV infection (P< 0.05). Conclusion: The treatment of HPV infection by CKC is related to the patient’s age and HPV subtype but not to number of pregnancies, number of pregnancies, number of vaginal deliveries, size of surgical specimens, and marginal conditions. The rate of HPV negative conversion is relatively high 24 months after the patient does not undergo surgery, but there is currently a lack of data on cervical lesions that match HPV results.